Novartis Reports Results of Aimovig (erenumab) in P-lV Study for Episodic and Chronic Migraine

Shots:

  • The P-IV HER-MES study involves assessing Aimovig (erenumab 70mg and 140mg) vs topiramate in 777 patients in a ratio (1:1) with episodic or chronic migraine (≥4 migraine days/month) prior not treated with migraine prevention treatment or previously failed up to three prophylactic migraine treatments
  • The study met its 1EPs & 2EPs and had superior tolerability against topiramate, with a higher proportion of patients remaining on Aimovig than on topiramate. The therapy showed superior efficacy, with a greater proportion of patients achieving at least a 50% reduction in their MMDs
  • Aimovig is the first EMA, Swissmedic, and US FDA’s approved migraine prevention treatment designed to target CGRP-R

Click here to­ read the full press release/ article | Ref: GlobeNewswire | Image: Caixin Global

The post Novartis Reports Results of Aimovig (erenumab) in P-lV Study for Episodic and Chronic Migraine first appeared on PharmaShots.

Drugs for Migraine

Date: 
October 5, 2020

Issue #: 

1608

Summary: 
An oral nonopioid analgesic is often sufficient for acute
treatment of mild to moderate migraine headache
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine headache pain in most patients without
vascular disease. Early treatment of pain when it is
still mild to moderate in intensity improves headache
response and reduces the risk of recurrence.